Tarsus Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Tarsus Pharmaceuticals's earnings have been declining at an average annual rate of -56.9%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 41.6% per year.
Key information
-56.9%
Earnings growth rate
-12.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 41.6% |
| Return on equity | -56.6% |
| Net Margin | -103.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Tarsus: Promising Investment, But Timing Is The Key
Jan 23Tarsus Pharmaceuticals: Early Rollout Exceeding Expectations
Dec 10US$65.33 - That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results
Nov 16
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41%
Nov 07Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money
Nov 05Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable
Sep 05Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
Aug 20With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For
Jun 26Following Up On Tarsus Pharmaceuticals
May 28Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results
May 11Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name
Mar 08Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic
Mar 03Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 01Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
Nov 12What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates
Aug 16Revenue & Expenses Breakdown
How Tarsus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 130 | -134 | 211 | 0 |
| 30 Jun 24 | 83 | -150 | 184 | 0 |
| 31 Mar 24 | 43 | -148 | 145 | 0 |
| 31 Dec 23 | 17 | -136 | 109 | 0 |
| 30 Sep 23 | 14 | -108 | 80 | 0 |
| 30 Jun 23 | 13 | -91 | 62 | 0 |
| 31 Mar 23 | 28 | -65 | 52 | 12 |
| 31 Dec 22 | 26 | -62 | 45 | 0 |
| 30 Sep 22 | 16 | -63 | 37 | 0 |
| 30 Jun 22 | 17 | -56 | 32 | 0 |
| 31 Mar 22 | 24 | -44 | 28 | 0 |
| 31 Dec 21 | 57 | -14 | 25 | 0 |
| 30 Sep 21 | 57 | -10 | 23 | 0 |
| 30 Jun 21 | 55 | -5 | 18 | 0 |
| 31 Mar 21 | 33 | -15 | 13 | -2 |
| 31 Dec 20 | 0 | -27 | 8 | 0 |
| 30 Sep 20 | 0 | -17 | 5 | 1 |
| 30 Jun 20 | 0 | -7 | 3 | 1 |
| 31 Mar 20 | 0 | -5 | 1 | 4 |
| 31 Dec 19 | 0 | -5 | 1 | 3 |
Quality Earnings: TARS is currently unprofitable.
Growing Profit Margin: TARS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TARS is unprofitable, and losses have increased over the past 5 years at a rate of 56.9% per year.
Accelerating Growth: Unable to compare TARS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TARS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (42%).
Return on Equity
High ROE: TARS has a negative Return on Equity (-56.57%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 02:48 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tarsus Pharmaceuticals, Inc. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Jason Matthew Gerberry | BofA Global Research |